Younger age at initiation of the human papillomavirus (HPV) vaccination series is associated with higher rates of on-time completion

Preventive Medicine

Volumn 89, Issue , 2016, Pages 327-333

  St Sauver, Jennifer L ^a,b   Rutten, Lila J Finney ^a,b   Ebbert, Jon O ^a,b   Jacobson, Debra J ^a,b   McGree, Michaela E ^a,b   Jacobson, Robert M ^a,b  

^a MAYO CLINIC   (United States)

^b Mayo Clinic College of Medicine   (United States)

Author keywords

Immunization; Immunization programs; Papillomavirus vaccines, vaccination; Patient acceptance of health care; Patient compliance

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGE; AGE DISTRIBUTION; ARTICLE; CHILD; CONTROLLED STUDY; ETHNICITY; FEMALE; FISHER EXACT TEST; HEALTH CARE SYSTEM; HEALTH INSURANCE; HEALTH SERVICE; HUMAN; IMMUNIZATION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PAPILLOMAVIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; RANK SUM TEST; SCHOOL CHILD; SEX DIFFERENCE; TIME TO TREATMENT; VACCINATION; YOUNG ADULT; MINNESOTA; PAPILLOMAVIRUS INFECTIONS; PATIENT ATTITUDE; PREVENTIVE HEALTH SERVICE; PROCEDURES;

ADOLESCENT; ADULT; AGE FACTORS; CHILD; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; MALE; MINNESOTA; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PATIENT ACCEPTANCE OF HEALTH CARE; VACCINATION;

EID: 84959868730     PISSN: 00917435     EISSN: 10960260     Source Type: Journal    
DOI: 10.1016/j.ypmed.2016.02.039     Document Type: Article

References (32)

1. Block, S.L., Nolan, T., Sattler, C., Barr, E., Giacoletti, K.E., Marchant, C.D., Castellsague, X., Rusche, S.A., Lukac, S., Bryan, J.T., Cavanaugh, P.F. Jr., Reisinger, K.S., Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 118 (2006), 2135–2145.
2. Centers for Disease Control and Prevention, FDA licensure of bivalent human papillomavirus vaccine (HPV2, cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly Rep. 59 (2010), 626–629.
3. Centers for Disease Control and Prevention, FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly Rep. 59 (2010), 630–632.
4. Centers for Disease Control and Prevention, General recommendations on immunization — recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly Rep. 60 (2011), 1–64.
5. Centers for Disease Control and Prevention, Human papillomavirus-associated cancers — United States, 2004–2008. MMWR Morb. Mortal. Wkly Rep. 61 (2012), 258–261.
6. Centers for Disease Control and Prevention, National and state vaccination coverage among adolescents aged 13–17 years—United States, 2012. MMWR Morb. Mortal. Wkly Rep. 62 (2013), 685–693.
7. Chaturvedi, A.K., Engels, E.A., Pfeiffer, R.M., Hernandez, B.Y., Xiao, W.H., Kim, E., Jiang, B., Goodman, M.T., Sibug-Saber, M., Cozen, W., Liu, L.H., Lynch, C.F., Wentzensen, N., Jordan, R.C., Altekruse, S., Anderson, W.F., Rosenberg, P.S., Gillison, M.L., Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J. Clin. Oncol. 29 (2011), 4294–4301.
8. D'Addario, M., Scott, P., Redmond, S., Low, N., HPV vaccines:systematic review of literature on alternative vaccination schedules. Organization, W.H., (eds.) Evidence Based Recommendations on Human Papilloma Virus (HPV) Vaccines Schedules. Background Paper for SAGE Discussions, 2014, Institute of Social and Preventive Medicine (ISPM), Bern.
9. Dunne, E.F., Stokley, S., Chen, W., Zhou, F., Human papillomavirus vaccination of females in a large health claims database in the United States, 2006–2012. J. Adolesc. Health 56 (2015), 408–413.
10. Ferris, D., Samakoses, R., Block, S.L., Lazcano-Ponce, E., Restrepo, J.A., Reisinger, K.S., Mehlsen, J., Chatterjee, A., Iversen, O.E., Sings, H.L., Shou, Q., Sausser, T.A., Saah, A., Long-term study of a quadrivalent human papillomavirus vaccine. Pediatrics 134 (2014), e657–665.
11. Giuliano, A.R., Lazcano-Ponce, E., Villa, L., Nolan, T., Marchant, C., Radley, D., Golm, G., McCarroll, K., Yu, J., Esser, M.T., Vuocolo, S.C., Barr, E., Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine. J. Infect. Dis. 196 (2007), 1153–1162.
12. Hariri, S., Unger, E.R., Sternberg, M., Dunne, E.F., Swan, D., Patel, S., Markowitz, L.E., Prevalence of genital human papillomavirus among females in the United States, the National Health And Nutrition Examination Survey, 2003–2006. J. Infect. Dis. 204 (2011), 566–573.
13. Herrero, R., Wacholder, S., Rodriguez, A.C., Solomon, D., Gonzalez, P., Kreimer, A.R., Porras, C., Schussler, J., Jimenez, S., Sherman, M.E., Quint, W., Schiller, J.T., Lowy, D.R., Schiffman, M., Hildesheim, A., Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discov. 1 (2011), 408–419.
14. Hirth, J.M., Tan, A., Wilkinson, G.S., Berenson, A.B., Completion of the human papillomavirus vaccine series among insured females between 2006 and 2009. Cancer 118 (2012), 5623–5629.
15. Hirth, J.M., Tan, A., Wilkinson, G.S., Berenson, A.B., Completion of the human papillomavirus (HPV) vaccine series among males with private insurance between 2006 and 2009. Vaccine 31 (2013), 1138–1140.
16. Jacobson, R.M., Rogacki, B., Thompson, D.M., Roberts, J.R., Margolis, B., Darden, P.M., Vaccination rates among adolescents in Minnesota as compared with the United States: not “above average”. Minn. Med. 98 (2015), 38–43.
17. Jayaprakash, V., Reid, M., Hatton, E., Merzianu, M., Rigual, N., Marshall, J., Gill, S., Frustino, J., Wilding, G., Loree, T., Popat, S., Sullivan, M., Human papillomavirus types 16 and 18 in epithelial dysplasia of oral cavity and oropharynx: a meta-analysis, 1985–2010. Oral Oncol. 47 (2011), 1048–1054.
18. Joura, E.A., Giuliano, A.R., Iversen, O.E., Bouchard, C., Mao, C., Mehlsen, J., Moreira, E.D. Jr., Ngan, Y., Petersen, L.K., Lazcano-Ponce, E., Pitisuttithum, P., Restrepo, J.A., Stuart, G., Woelber, L., Yang, Y.C., Cuzick, J., Garland, S.M., Huh, W., Kjaer, S.K., Bautista, O.M., Chan, I.S., Chen, J., Gesser, R., Moeller, E., Ritter, M., Vuocolo, S., Luxembourg, A., A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N. Engl. J. Med. 372 (2015), 711–723.
19. Kreimer, A.R., Struyf, F., Del Rosario-Raymundo, M.R., Hildesheim, A., Skinner, S.R., Wacholder, S., Garland, S.M., Herrero, R., David, M.P., Wheeler, C.M., Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica vaccine and PATRICIA trials. Lancet Oncol. 16 (2015), 775–786.
20. Lowy, D.R., Solomon, D., Hildesheim, A., Schiller, J.T., Schiffman, M., Human papillomavirus infection and the primary and secondary prevention of cervical cancer. Cancer 113 (2008), 1980–1993.
21. Markowitz, L.E., Dunne, E.F., Saraiya, M., Lawson, H.W., Chesson, H., Unger, E.R., Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly Rep. 56 (2007), 1–24.
22. Markowitz, L.E., Dunne, E.F., Saraiya, M., Chesson, H.W., Curtis, C.R., Gee, J., Bocchini, J.A. Jr., Unger, E.R., Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly Rep. 63 (2014), 1–30.
23. Munoz, N., Bosch, F.X., Castellsague, X., Diaz, M., De Sanjose, S., Hammouda, D., Shah, K.V., Meijer, C.J.L.M., Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int. J. Cancer 111 (2004), 278–285.
24. Naud, P.S., Roteli-Martins, C.M., De Carvalho, N.S., Teixeira, J.C., de Borba, P.C., Sanchez, N., Zahaf, T., Catteau, G., Geeraerts, B., Descamps, D., Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum. Vaccin. Immunother. 10 (2014), 2147–2162.
25. Reagan-Steiner, S., Yankey, D., Jeyarajah, J., Elam-Evans, L.D., Singleton, J.A., Curtis, C.R., MacNeil, J., Markowitz, L.E., Stokley, S., National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years—United States, 2014. MMWR Morb. Mortal. Wkly Rep. 64 (2015), 784–792.
26. Reisinger, K.S., Block, S.L., Lazcano-Ponce, E., Samakoses, R., Esser, M.T., Erick, J., Puchalski, D., Giacoletti, K.E.D., Sings, H.L., Lukac, S., Alvarez, F.B., Barr, E., Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents — a randomized controlled trial. Pediatr. Infect. Dis. J. 26 (2007), 201–209.
27. Rubin, R.F., Kuttab, H.M., Rihani, R.S., Reutzel, T.J., Patient adherence to three dose completion of the quadrivalent human papillomavirus (HPV) vaccine in a private practice. J. Community Health 37 (2012), 1145–1150.
28. Sankaranarayanan, R., Prabhu, P.R., Pawlita, M., Gheit, T., Bhatla, N., Muwonge, R., Nene, B.M., Esmy, P.O., Joshi, S., Poli, U.R., Jivarajani, P., Verma, Y., Zomawia, E., Siddiqi, M., Shastri, S.S., Jayant, K., Malvi, S.G., Lucas, E., Michel, A., Butt, J., Vijayamma, J.M., Sankaran, S., Kannan, T.P., Varghese, R., Divate, U., Thomas, S., Joshi, G., Willhauck-Fleckenstein, M., Waterboer, T., Muller, M., Sehr, P., Hingmire, S., Kriplani, A., Mishra, G., Pimple, S., Jadhav, R., Sauvaget, C., Tommasino, M., Pillai, M.R., Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study. Lancet Oncol. 17 (2016), 67–77.
29. Schiffman, M., Castle, P.E., Jeronimo, J., Rodriguez, A.C., Wacholder, S., Human papillomavirus and cervical cancer. Lancet 370 (2007), 890–907.
30. St Sauver, J.L., Grossardt, B.R., Yawn, B.P., Melton, L.J. III, Rocca, W.A., Use of a medical records linkage system to enumerate a dynamic population over time: the Rochester Epidemiology Project. Am. J. Epidemiol. 173 (2011), 1059–1068.
31. St Sauver, J.L., Grossardt, B.R., Yawn, B.P., Melton, L.J. III, Pankratz, J.J., Brue, S.M., Rocca, W.A., Data resource profile: the Rochester Epidemiology Project (REP) medical records-linkage system. Int. J. Epidemiol. 41 (2012), 1614–1624.
32. World Health Organization, Human papillomavirus vaccines: WHO position paper, October 2014-recommendations. Vaccine 33 (2015), 4383–4384.